Management of rising prostate-specific antigen after a negative biopsy. - Wikidata - wikimedia - TriplyDB

Management of rising prostate-specific antigen after a negative biopsy.

Management of rising prostate-specific antigen after a negative biopsy.

http://www.wikidata.org/entity/Q37846119

about

BMI1, stem cell factor acting as novel serum-biomarker for Caucasian and African-American prostate cancer.Markers of field cancerization: proposed clinical applications in prostate biopsies High-Resolution Rapid Diagnostic Imaging of Whole Prostate Biopsies Using Video-Rate Fluorescence Structured Illumination Microscopy Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.Video-rate structured illumination microscopy for high-throughput imaging of large tissue areas Prostate saturation biopsy following a first negative biopsy: state of the art.Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of prostate cancer patients.Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.

P2860

Q34544617-4EA22837-530C-4035-A4BB-D732E3F0B80A Q35991148-EF560131-B406-449C-8D28-C84F3E1F9E02 Q36118034-3EF50599-BAD1-4EA0-B2BB-4C0504879D04 Q36931205-80F83DCC-0245-4C76-A350-DE4596A8E408 Q37577297-A597FBD8-95CE-4A4F-9571-6A8385E90CBE Q38027698-D06648E6-19D7-49F3-8E05-DCF797323CBD Q45323416-DAA5920C-BDFA-4513-ADAF-2B5DFC5550EA Q53801746-69F22431-CC25-4F8C-9885-266437A17D22

P2860

Management of rising prostate-specific antigen after a negative biopsy.

http://www.wikidata.org/entity/Q37846119

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Management of rising prostate-specific antigen after a negative biopsy.

@en

Management of rising prostate-specific antigen after a negative biopsy.

@nl

type

label

Management of rising prostate-specific antigen after a negative biopsy.

@en

Management of rising prostate-specific antigen after a negative biopsy.

@nl

prefLabel

Management of rising prostate-specific antigen after a negative biopsy.

@en

Management of rising prostate-specific antigen after a negative biopsy.

@nl

P1433

Q37846119-772B10C8-C52A-46F9-BE9A-8CECD50990E9

P1476

Q37846119-9B1FE5F5-C5C3-4924-B8A0-51C3EA67BD0C

P2093

Q37846119-6A5FE718-D6DD-4CC7-8FE4-AA785F682E11

Q37846119-A59F7571-CF1B-4B28-A277-DBC28F07DEE1

P2860

Q37846119-03236DE4-5F37-4046-B0A1-D6FBBFEDF543

Q37846119-06DBCB92-3A94-43A3-AEAD-339E9A629D09

Q37846119-1E076DA4-0729-493A-9C9E-26B8B7CE8467

Q37846119-2257CA57-C2EF-4617-815B-3FB9B7CF2340

Q37846119-67420EA6-BB96-401D-9624-609BFB8EDE11

Q37846119-69B73018-BB13-4B28-A2CF-527EAAD9A084

Q37846119-6BA77806-A77D-4963-B86E-60D2585C0477

Q37846119-6CDE550D-3699-4F40-AEB4-F3D319566781

Q37846119-6F7055DC-02AA-4C0C-9BB1-FDCC7FE9CDC0

Q37846119-818AA1C4-E884-4774-AE6A-5675880F5770

P2888

Q37846119-776EDE94-84DF-4326-B98F-C7F815E766DE

P304

Q37846119-15DAA1FF-AC63-4767-B2E9-E97B14D8D328

P31

Q37846119-26372AE0-7EB6-4697-8447-136933ECEA59

P356

Q37846119-26311D5D-11C1-4EDF-A2DE-C5C09A04EC8F

P433

Q37846119-A74A19E8-73BF-4663-9364-E8D5056A8885

P478

Q37846119-C30A260F-0445-4300-8364-28FE15244E18

P577

Q37846119-EE853E26-94A8-4607-AF33-1EE60BE4FF07

P698

Q37846119-8366B565-89B3-432E-AB9A-F089117BDFDE

P921

Q37846119-4621F471-F386-4B0C-8BEA-43020A3CD36B

P356

S11934-011-0177-1

P1433

Current urology reports

P1476

Management of rising prostate-specific antigen after a negative biopsy.

@en

P2093

David A Levy

http://www.w3.org/2001/XMLSchema#string

J Stephen Jones

http://www.w3.org/2001/XMLSchema#string

P2860

Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate

Effect of dutasteride on the risk of prostate cancer.

Computer-assisted diagnosis of prostate cancer using DCE-MRI data: design, implementation and preliminary results.

Re-biopsy of the prostate using a stereotactic transperineal technique.

Prostate cancer detection with office based saturation biopsy in a repeat biopsy population.

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Improved prostate cancer detection with anterior apical prostate biopsies.

The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer.

Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy.

Complication rate of transrectal ultrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores.

P2888

s11934-011-0177-1

P304

197-202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11934-011-0177-1

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21344195

http://www.w3.org/2001/XMLSchema#string

P921